Calcyphosine 1/CAPS1 Polyclonal Antibody

Applications

  • WB
  • ELISA
  • IHC-P
  • IHC-F
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)
  • ICC

Reactivity

  • Human

Predicted Reactivity

  • Dog
  • Cow
  • Sheep
  • Pig
  • Rabbit
Overview
Catalog # bs-12161R
Product Name Calcyphosine 1/CAPS1 Polyclonal Antibody
Applications WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC
Reactivity Human
Predicted Reactivity Dog, Cow, Sheep, Pig, Rabbit
Specifications
Conjugation Unconjugated
Host Rabbit
Source KLH conjugated synthetic peptide derived from human Calcyphosine 1
Immunogen Range 101-189/189
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide.
Storage Condition Store at -20°C for 12 months..
Target
Subcellular location Cytoplasm
Synonyms Calcyphosin; Calcyphosine 1; Calcyphosine; CAPS; CAPS1; CAYP1_HUMAN; Thyroid protein p24.
Background CAPS1 is a 189 amino acid cytoplasmic protein that contains four EF-hand domains, which serve as calcium-binding sites, and was first identified in canine thyroid. Interestingly, CAPS1 is much less abundant in humans than in canines. Synthesis and phosphorylation of CAPS1 is upregulated by cAMP-agonists in thyrocytes. CAPS1 likely functions in the regulation of ionic transport and may be involved in cross-signaling between cAMP and Ca(+2)-phophatidylinositol cascades. In addition to thyriod, CAPS1 is expressed in brain, salivary glands and lung. Expression of CAPS1 is increased in endometrial cancer and prognosis seems to be dependent on the level of CAPS1 expression, indicating that CAPS1 may be an appropriate prognostic marker for patient survival.
Application Dilution
WB 1:300-1000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500